KAHD and Lapatinib for prostate cancer – pro
KAHD referes to a combination of drugs. Ketoconazole, Hydrocortisone, Dutasteride With Lapatinib it is also in a clincal trial: (KHAD-L) in Prostate Cancer, NCT00953576
The purpose of this research study is to determine the safety of giving ketoconazole, hydrocortisone and dutasteride (KHAD) with lapatinib. The investigators believe that there is evidence in castrate resistant prostate cancer that two growth factor receptors (EGFr and Her 2 /neu )are increased in prostate cancer cells. Both these receptors are turned off by the drug lapatanib. By adding lapatinib to this trial, the investigators hope that the investigators can turn off the signaling from the receptors and therefore make the participant’s cancer more responsive to KHAD treatment.
An abstract of KHAD was presented at ASCO 2008. The response rate was equivalent or superior to historical controls, and time to progression was prolonged compared to published durations of 3.5-8.6 months for K/H. . The investigators concluded: “These data indicate that addition of D to further suppress intratumor androgen synthesis may result in improved responses, and support a randomized trial to compare KHAD with standard K/H”.
M. Taplin, Y. Ko, M. M. Regan, T. M. Beer, M. A. Carducci, P. Mathew, G. Bubley, W. K. Oh, P. W. Kantoff, S. P. Balk Phase II trial of ketoconazole, hydrocortisone, and dutasteride (KHAD) for castration resistant prostate cancer (CRPC).J Clin Oncol 26: 2008 (May 20 suppl; abstr 5068)
Yu Chen et al, Antiandrogens and androgen depleting therapies in prostate cancer: novel agents for an established target Lancet Oncol. 2009 October; 10(10): 981–991.